4-methylmorpholin-4-ium 2,2,2-trifluoroacetate | 393590-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-methylmorpholin-4-ium 2,2,2-trifluoroacetate
• 英文别名: 4-methylmorpholin-4-ium Trifluoroacetat；methylmorpholin-4-ium trifluoroacetate；NMM*TFA；N-methylmorpholinium trifluoroacetate；4-methylmorpholin-4-ium;2,2,2-trifluoroacetate
• CAS: 393590-33-5
• 化学式: C₂HF₃O₂*C₅H₁₁NO
• 分子量: 215.172
• InChiKey: FYJPZSUDLPCERB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.17
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  53.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS
  申请人：Boueres Julia

  公开号：US20110201657A1

  公开（公告）日：2011-08-18

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

  本发明涉及公式（I）的化合物及其药学上可接受的盐或互变异构体，这些化合物是聚（ADP核糖）聚合酶（PARP）的抑制剂，因此可用于治疗癌症、炎症性疾病、再灌注损伤、缺血性疾病、中风、肾衰竭、心血管疾病、除心血管疾病外的其他血管疾病、糖尿病、神经退行性疾病、逆转录病毒感染、视网膜损伤或皮肤衰老和紫外线诱导的皮肤损伤的治疗，以及作为癌症治疗的化疗或放疗增敏剂。
• Devices and method for amino acid sequence determination
  申请人：GENENTECH, INC.

  公开号：EP0257735A2

  公开（公告）日：1988-03-02

  A device for the determination of amino acid sequence of a polypeptide comprises two new features offering great advantages in the cost and efficiency of operation of amino acid sequencers: The sequencer is provided with the capability for the bidirectional flow of sequencing reagents and contains a sample chamber having a bicompositional adsorbent for the polypeptide.

  一种用于测定多肽氨基酸序列的装置具有两个新特点，在氨基酸测序仪的成本和运行效率方面具有极大的优势：测序仪具有测序试剂双向流动的能力，并包含一个具有多肽双组分吸附剂的样品室。
• Pharmaceutical composition for diseases caused by vasoconstriction
  申请人：KOWA COMPANY, LTD.

  公开号：EP0384144B1

  公开（公告）日：1996-04-03